The article you requested is

A Case of Complex Movement Disorder Induced by Fluoxetine With Management of Dystonia by Botulinum Toxin Type A

J Clin Psychiatry 2005;66(2):267-268 [letter]

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Selective serotonin reuptake inhibitors (SSRIs) have been associated with movement disorders such as akathisia, dystonia, dyskinesia, and parkinsonism.1–3 We present a case of fluoxetine-induced de novo complex movement disorder characterized by orofacial dyskinesia, jaw-closing dystonia, bruxism, and parkinsonism. Focal injections of botulinum toxin type A (BTX-A) were required to treat the dystonic features.​